Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting

Antibody therapy is a validated treatment approach for several malignancies. All currently clinically applied therapeutic antibodies (Abs) are of the IgG isotype. However, not all patients respond to this therapy and relapses can occur. IgA represents an alternative isotype for antibody therapy that...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:MAbs
Päätekijät: Meyer, Saskia, Nederend, Maaike, Jansen, J.H. Marco, Reiding, Karli R., Jacobino, Shamir R., Meeldijk, Jan, Bovenschen, Niels, Wuhrer, Manfred, Valerius, Thomas, Ubink, Ruud, Boross, Peter, Rouwendal, Gerard, Leusen, Jeanette H.W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2015
Aiheet:
Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966554/
https://ncbi.nlm.nih.gov/pubmed/26466856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1106658
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia